Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04385368
Title	Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)
Acronym	MERMAID-1
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-small cell carcinoma
Therapies	Durvalumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUS \| ARG